BioSpace News Archive

TFF Pharmaceuticals, Inc. today announced that President and CEO Glenn Mattes will present a corporate overview at the SNN Virtual Investor Conference being held August 17 – 19, 2021.

NLS Pharmaceutics Ltd. announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present at the Canaccord Genuity 41 st Annual Growth Conference being held virtually August 10-12, 2021.

Hillstream BioPharma, Inc. today announced the signing of a non-binding term sheet with Minotaur Therapeutics (“Minotaur”) to advance the development of the next generation targeted Knob biologics for undruggable targets including c-MYC combined with Hillstream’s tumor-targeting Quatramers™.

Inspired Spine published a peer-reviewed study of perioperative outcomes of minimally invasive sacroiliac joint fusion using hollow screws through a lateral approach: A single surgeon retrospective cohort study.

China Pharma Holdings, Inc., a specialty pharmaceutical company, announced that its Candesartan hypertension product passed key bioequivalence tests.

Synlogic, Inc.today announced the Company will release its second quarter 2021 financial results before the market opens on Thursday, August 12, 2021 .

Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021.

Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced that Craig Parker, chief executive officer, will provide a company overview and a business update at Canaccord Genuity’s 41st Annual Growth Conference at 9:30 a.m. ET on Thursday, August 12.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the second quarter ending June 30, 2021 and provided an update on clinical and corporate activities.

Aardvark Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications announced the successful completion of a $29 million Series B financing.